Search All News
A new study conducted at Columbia and other centers found that 80% of patients with a type of slow-growing lymphoma achieved a complete remission with a single infusion of CAR T-cell immunotherapy.
Immunotherapy, often ineffective against stomach cancer, was more effective when combined with chemotherapy and given earlier, finds a new study in mice.
Columbia biomedical engineers have designed a bacteria strain that seeks out solid tumors and safely delivers immunotherapies, resulting in tumor regression in mouse models.
Columbia researchers found that a gene associated with an autoimmune form of hair loss could be activated to improve cancer immunotherapy.
- June 29, 2018
Cell-based therapy expert Pawel Muranski, MD, discusses the challenges of testing cancer immunotherapy drugs in new patient groups.
- September 7, 2017
Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.
- August 30, 2017
Immunotherapy expert Pawel Muranski speaks about the new CAR-T therapy for leukemia and his work to bring T cell therapies to patients with a wide range of cancers.
- August 30, 2017
Prakash Satwani, MD, leads NYP/CUIMC's program in CAR-T therapy, a new treatment that uses a patient's own T cells to attack cancer.
- February 27, 2017
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.
- October 5, 2015
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
- March 12, 2015
Advances in how the immune system can be harnessed to fight cancer offer new hope to patients with lung cancer.